AMRX compared with XPER: revenue, margins and what each company keeps, and the suppliers and customers both name

AMRXAmneal Pharmaceuticals, Inc.

Mkt capRevenueRevenue

XPERXperi Inc.

Mkt capRevenueRevenue

Compare

AMRXAmneal Pharmaceuticals, Inc.

XPERXperi Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

XPER: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

AMRX, solidXPER, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMRX 14

—Customer Aunlistedcustomer

—Kashiv Biosciencesunlistedsupplier

—ApiJect Systemsunlistedsupplier

—BIAL-Portela & Caunlistedsupplier

10 more · AMRX chain ›

Shared 0

No shared counterparties.

Only XPER 1

PNCPNC Bank, National Associationsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

AMRXAmneal Pharmaceuticals, Inc.

21.50▲+0.70%· post 21.43

Mkt cap$6.9BRevenue$796MQ2 FY26Revenue$3.0BFY25

XPERXperi Inc.

5.31▼−2.13%· post 5.31

ClosedOct 30 '26

Mkt cap$258.1MRevenue$114MQ2 FY26Revenue$448MFY25

Compare

ClosedOct 30 '26

AMRXAmneal Pharmaceuticals, Inc.

XPERXperi Inc.

21.50▲+0.70%post 21.43

Price

5.31▼−2.13%post 5.31

$6.9B

Mkt cap

$258.1M

Q2 FY26$796M

Revenue

$114MQ2 FY26

FY25$3.0B

Revenue

$448MFY25

AMRX21.50▲+0.70%vsXPER5.31▼−2.13%ClosedOct 30 '26